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Center for Pathobiochemistry and Genetics, Medical University of Vienna, AustriaBackground & Aims: Cholestasis is characterized by intrahepatic and thereby protects BSEP/ mice from cholestatic liver and bile
accumulation of potentially cytotoxic bile acids (BAs) subse-
quently leading to liver injury with disruption of hepatocellular
integrity, inflammation, fibrosis and ultimately liver cirrhosis.
Bile salt export pump (BSEP/ABCB11) is the main canalicular BA
transporter and therefore the rate limiting step for hepatobiliary
BA excretion. In this study we aimed to investigate the role of
BSEP/ABCB11 in the development of acquired cholestatic liver
and bile duct injury.
Methods:Wild-type (WT) and BSEP knockout (BSEP/) mice
were subjected to common bile duct ligation (CBDL) or 3.5-die
thoxycarbonyl-1.4-dihydrocollidine (DDC) feeding as models for
cholestasis with biliary obstruction and bile duct injury. mRNA
expression profile, serum biochemistry, liver histology, immuno-
histochemistry, hepatic hydroxyproline levels and BA composi-
tion as well as biliary pressure were assessed.
Results: BSEP/ mice were protected against acquired chole-
static liver injury induced by 7 days of CBDL or 4 weeks of DDC
feeding, as reflected by unchanged serum levels of liver transam-
inases, alkaline phosphatase and BAs. Notably, BSEP/mice were
also protected from cholestasis-induced hepatic inflammation
and biliary fibrosis. In line with induced BA detoxification/
hydroxylation pathways in BSEP/ mice, polyhydroxylated BAs
were increased 4-fold after CBDL and 6-fold after DDC feeding
in comparison with cholestatic WT mice. Finally, following CBDL,
biliary pressure in WT mice increased up to 47 mmH2O but
remained below 11 mmH2O in BSEP/ mice.
Conclusion:Metabolic preconditioning with subsequent changes
in BA metabolism favors detoxification of potentially toxic BAsJournal of Hepatology 20
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Lay summary: Reduced hepatobiliary bile acid transport due to
loss of BSEP function leads to increased hydroxylation of bile acids
in the liver.Metabolic preconditioningwith a hydrophilic bile pool
protects the BSEP/ mice from acquired cholestatic liver disease.
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by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Impairment of the canalicular bile acid (BA) transport via the bile
salt export pump (BSEP/ABCB11) is a well appreciated cause of
cholestasis [1,2]. Absence of BSEP in humans causes progressive
familial intrahepatic cholestasis type 2 (PFIC2), a severe chole-
static liver disease in children that may require liver transplanta-
tion or can lead to death [3,4]. In contrast to humans, this genetic
defect in mice is associated with a milder phenotype lacking the
development of progressive cholestasis [5]. This finding may at
least in part be explained by differences in BA composition, meta-
bolism and transporters between mice and men [5]. Importantly,
BSEP deficient mice develop adaptive mechanisms of BA metabo-
lism and transport, including increased BA hydroxylation and
increased biliary cholesterol and phospholipid output [6,7],
which may protect against development of cholestatic liver and
bile duct injury. However, it is unclear; (i) if such changes in BA
homeostasis may precondition and thereby protect mice born
with this gene defect against acquired cholestatic liver and bile
duct injury after birth; and (ii) whether such mechanisms may
be useful for the development of novel therapeutic strategies
against cholestasis and cholangiopathies.
Therefore, the present study was designed to explore the
hypothesis that absence of BSEP causes adaptive mechanisms of
BA metabolism which protect against acute (common bile duct
ligation, CBDL) and chronic (3.5-diethoxycarbonyl-1.4-dihydrocol
lidine feeding, DCC) cholestatic liver and bile duct injury. We17 vol. 66 j 95–101
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hypothesized that inborn BSEP deficiency via an adaptive
increase of polyhydroxylated BAs may precondition and thereby
protect against acquired cholestatic liver and bile duct injury.Materials and methods
Animal experiments
Experiments were performed in 2-month-old male BSEP/ mice and WT litter-
mates (FVB/N background) kindly provided by Victor Ling, Vancouver, Canada
and housed in a 12 h light/dark house facility with water and standard chow diet
(SSNIFF, Soest, Germany) ad libitum. The experimental protocols were approved
by the local Animal Care and Use Committee (BMWFW-66.009/0008-
WF/3b/2015). CBDL, DDC feeding, mouse harvesting, and serum biochemical
analysis were performed as previously described in detail [8,9]. Unless stated
other, the number of mice per group ranged from 5 to 7.
Histology
For conventional light microscopy, livers were fixed in 4% neutral buffered
formaldehyde solution for 24 h and embedded in paraffin. Sections were cut
3 lm thick and stained with hematoxylin and eosin (H&E) or Sirius Red as
described [10].
Immunohistochemistry
Detection of the cholangiocyte marker cytokeratin 19 (CK19) and proliferation
marker Ki67 was performed as described previously [11].
Bile acid profiling by UPLC-MS/MS
Profiles of liver BAs were analyzed on an Applied Biosystems AB SCIEX QTRAP
5500 platform as published previously [12]. Unconjugated and taurine-
conjugated tetra- and pentahydroxylated BAs were identified from their molecu-
lar anions at m/z 463, 479, 530 and 546, respectively, and quantified in relation to
D4-CA and D4-taurocholic acid (TCA).
Messenger RNA analysis and polymerase chain reaction (PCR)
RNA isolation from liver, complementary DNA synthesis and real-time PCR were
performed as described previously [13]. Oligonucleotide sequences are available
upon request.
Western blot analysis
Protein expression analysis was performed as described previously [14].
Hepatic hydroxyproline content
To quantify liver fibrosis, hepatic hydroxyproline was measured from a standard-
ized liver lobe as described previously [15].
Cholangiomanometry
Biliary pressure measurements were performed 7 days after CBDL. The common
bile duct was ligated just before entering the duodenum. After median laparo-
tomy, a small catheter (PE Fine-Bore Polyethylene tubing, ID 0.28 mm, OD
0.61 mm, Smith Medical, Kent, UK) was inserted into the common bile duct
and fixed in place using a silk ligature. The catheter was connected to a high-
sensitive pressure transducer (MLT0380/D, ADInstruments, Colorado Springs,
CO, USA) and biliary pressure was continuously recorded (ML870 PowerLab
8/30, ADInstruments, Colorado Springs, CO, USA).
Microarray analysis
200 ng of total RNA were amplified and labeled using the GeneChip WT PLUS
Reagent Kit (Catalog Number 902281, Affymetrix, Santa Clara, CA). Affymetrix96 Journal of Hepatology 20GeneChip Mouse Gene 2.0 ST arrays were washed, stained and scanned accord-
ing to the protocol described in GeneChipWT Terminal Labeling and Hybridiza-
tion User Manual (Fluidics Protocol FS450_0002). Normalized expression data
were analyzed by Ingenuity Pathway Analysis software (Qiagen, Austria).Statistical analysis
Results were evaluated using SPSS v.20.0. Statistical analysis was performed
using one-way analysis of variance test followed by Student’s t test. If not other-
wise noted data are reported as means of 5 to 7 animals per group with standard
deviations. A p value 60.05 was considered statistically significant.Results
BSEP/ mice are protected from cholestatic liver injury
BSEP/ mice did not exhibit any histological signs of liver injury
after 7 days of CBDL or 4 weeks of DDC feeding (Fig. 1A and B). In
contrast, wild-type (WT) mice subjected to CBDL showed signs of
inflammation as well as bile infarcts (Fig. 1A, white arrow). More-
over, DDC fed WT mice showed pronounced signs of liver injury
such as inflammation and fibrosis. Liver histology of BSEP/mice
after DDC feeding remained normal (Fig. 1B). Notably, serum liver
transaminases (alanine aminotransferase [ALT]) and aspartate
aminotransferase [AST]) as markers of hepatocellular injury as
well as serum markers of cholestasis (AP, BAs), and bilirubin
remained unchanged in BSEP/ mice after CBDL and DDC, while
in WT mice these biochemical parameters were dramatically
increased (Fig. 1C, D and Supplementary Fig. 1). Of note, por-
phyrin plugs, typical for DDC feeding were found in both, WT
and BSEP/ mice (Fig. 1B).
BSEP/ mice do not develop hepatic inflammation after bile duct
ligation and DDC feeding
Since cholestasis and cholangiopathies are associated with hep-
atic inflammation, we next investigated mRNA expression levels
of inflammatory markers F4/80, Mcp1 as well as IL1b. Expression
levels of all the makers remained unchanged in BSEP/ mice
after CBDL and DDC feeding. In contrast, in WT CBDL mice
F4/80 was increased 4-fold, Mcp1 60-fold and IL1b 5-fold
(Fig. 2A); after DDC feeding F4/80 was increased 2.5-fold, Mcp1
60-fold and Il1b 4-fold in DDC fed WT mice (Fig. 2B). Interest-
ingly, expression profile of toll like receptor 4 (TLR4) did not dif-
fer between the groups, neither after CBDL, nor after DDC feeding
(data not shown).BSEP/ mice are protected against bile duct proliferation after CBDL
and DDC
Since hepatic inflammation is known to trigger cellular prolifer-
ation [16] we next investigated Ki67 immunohistochemistry
(IHC). In contrast to BSEP/ mice, in WT mice subjected to CBDL
or DDC, Ki67 expression was increased (Fig. 3A, B upper panel, C,
and D). In line, microarray data showed increased expression
levels of several genes involved in cell cycle (such as Cdk1 and
Ccna2) in WT CBDL mice (Supplementary Fig. 2). Of note, not only
hepatocytes but also cholangiocytes stained positive for Ki67
(Fig. 3A upper panel black arrow). Importantly, cytokeratin 19
(CK19) and Cftr (markers for proliferative bile ducts), remained
unremarkable in BSEP/ mice after bile duct ligation or DDC17 vol. 66 j 95–101
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Fig. 1. BSEP/ mice are protected against cholestatic liver injury induced by
bile duct ligation and DDC feeding. (A and B) Representative H&E images (10
magnification) with apparently unremarkable liver histology in BSEP/ mice
before and after (A) CBDL and (B) DDC feeding. While BSEP/ mice are
protected as indicated by normal liver histology, WT mice show inflammation
and bile infarcts (A white arrow) after CBDL and (B) portal inflammation and
fibrosis after DDC feeding. (C and D) Serum biochemistry after (C) CBDL and (D)
DDC feeding with increased serum levels of ALT, alkaline phosphatase (AP) and
BAs in WT mice but not in BSEP/ mice. #Significant difference from WT
control; ⁄significant difference from WT CBDL; p <0.05. Statistical analysis
was performed using one-way analysis of variance test followed by Student’s t
test.
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Fig. 2. BSEP/ mice are protected against inflammation after CBDL and DDC
feeding. (A and B) Real-time PCR was used to assess the mRNA expression of F4/
80,Mcp1 and IL1b as markers of inflammation after (A) CBDL and (B) DDC feeding.
In contrast to WT mice, BSEP/ CBDL mice and DDC fed mice did not show
increased expression levels of these inflammatory markers compared to the
control group. Expression values were normalized against 36b4 levels and are
shown relative to expression level in WT controls. #Significant difference from
WT Ctrl; ⁄significant difference from WT CBDL; p <0.05. Statistical analysis was
performed using one-way analysis of variance test followed by Student’s t test.
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Journal of Hepatology 20feeding, whereas in WTmice subjected to CBDL or DDC the mRNA
levels of both markers were significantly increased (Fig. 3E, F).
BSEP/ mice do not develop biliary fibrosis after bile duct ligation
and DDC feeding
Sirius Red staining exhibited fibrosis only in WT mice but not in
BSEP/ mice subjected to CBDL or DDC (Fig. 4A, B). Accordingly,
mRNA expression of fibrosis markers such as Col1a1, Col1a2 and
Tgfb were unaffected in BSEP/ mice after CBDL or DDC feeding.
Similar to inflammatory markers, fibrosis genes were upregulated
in WT CBDL compared to control mice (Col1a1 2fold; Col1a2 2,5-
fold, Tgfb 1, 8fold) (Fig. 4C). Moreover, hepatic hydroxyproline
content was increased only in WT CBDL mice (Fig. 4D). Further-
more, gene expression profile of fibrosis markers (Col1a1, Col1a2,
Tgfb) revealed development of liver injury exclusively in DDC fed
WT but not BSEP/ mice. mRNA expression of Col1a1, Col1a2 as
well as Tgfb (Fig. 4E) were increased after DDC feeding in WT but
not in BSEP/mice. Of note, also mRNA expression of Desmin fol-
lows the same direction under both conditions (data not shown).
Hydroxyproline content was increased only in WT DDC mice
(Fig. 4F). Absence of hepatic inflammation and fibrosis in BSEP/
mice after CBDL and DDC feeding was in line with unremarkable
serum biochemistry in these groups of mice, suggesting that
BSEP/ mice are protected from cholestatic liver injury.
BSEP/ mice are metabolically preconditioned with a non-toxic bile
acid pool
Since it is known that hydrophobic BAs are hepatotoxic we inves-
tigated potential changes of the hepatic BA profile in BSEP/17 vol. 66 j 95–101 97
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Fig. 3. BSEP/mice do not express markers of hepatocellular and ductular proliferation after CBDL and DDC feeding. (A and B) Ki67 and CK19 immunohistochemistry
(10 magnification) after (A) CBDL and (B) DDC feeding showed increased hepatocyte and cholangiocyte proliferation in challenged WT mice but not in BSEP/ mice. (C
and D) Quantification of Ki67 and CK19 positive cells revealed a significant increase in Ki76 and CK19 positive cells in WTmice after (C) CBDL and (D) DDC feeding. (E and F)
Real-time PCR was used to assess the mRNA expression of CK19 and Cftr as markers for ductular proliferation, in (E) CBDL and (F) DDC fed animals. Expression levels of both
markers were increased in WT mice by CBDL and DDC feeding, but remained unchanged in BSEP/ mice. Expression values were normalized against 36b4 levels and are
shown relative to expression level in unchallenged WT animals #Significant difference fromWT Ctrl; ⁄significant difference from WT CBDL; p <0.05. Statistical analysis was
performed using one-way analysis of variance test followed by Student’s t test.
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Fig. 4. BSEP/ mice are protected against biliary fibrosis after CBDL and DDC feeding. (A and B) Representative Sirius Red staining images (10 magnification) show
pronounced biliary fibrosis in WT mice after (A) CBDL and (B) DDC feeding. (C and E) Real-time PCR was used to assess the mRNA expression of fibrotic markers Col1a1,
Col1a2 and Tgfb. Expression levels of these markers were increased in WT mice due to CBDL and DDC feeding and not affected in BSEP/ mice. Expression values were
normalized against 36b4 levels and are shown relative to expression level in unchallenged WT animals. #Significant difference fromWT Ctrl; ⁄significant difference fromWT
CBDL; p <0.05. (D and F) OH-proline levels were assed in mice subjected to (D) CBDL and (F) DDC feeding. OH-proline did not change in BSEP/ mice after (D) CBDL mice
and (F) DDC feeding. In WT mice CBDL was followed by a 1.8-fold and DCC feeding by a 1.5-fold increase of OH-levels. #Significant difference from WT Ctrl; ⁄significant
difference from WT CBDL; p <0.05. Statistical analysis was performed using one-way analysis of variance test followed by Student’s t test.
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Table 1. Liver bile acids in WT and BSEP/ mice before and after common bile
duct ligation.
WT Ctrl 
[pmol/mg]
BSEP-/- Ctrl 
[pmol/mg]
WT BDL 
[pmol/mg]
BSEP-/- CBDL 
[pmol/mg]
TCA 307 ± 137 407 ± 32 89 ± 18# 34 ± 9*
TUDCA 3 ± 2 2 ± 2 3 ± 1 3 ± 1
THDCA 11 ± 2 8 ± 1 7 ± 1# 7 ± 1
TCDCA 2 ± 1 1 ± 0.5 4 ± 1 7 ± 0.1*
TDCA 10 ± 6 1 ± 2# n.d n.d
TLCA 0.1 ± 0.02 0.04 ± 0.01# 0.02 ± 0.01 0.05 ± 0.01*
CA 4 ± 5 n.d n.d n.d
TοMCA 76 ± 57 22 ± 12 33 ± 16 19 ± 4
TαMCA 15 ± 11 6 ± 2 14 ± 6 6 ± 1*
TβMCA 155 ± 121 329 ± 130 1163 ± 443# 652 ± 132
οMCA 2 ± 1 n.d n.d n.d
βMCA 2 ± 2 11 ± 7 9 ± 6 13 ± 4
T-Tetrols 4 ± 3 450 ± 172# 230 ± 102# 596 ± 58.35*
T-Pentols 0.06 ± 0.12 26 ± 7# 6 ± 3# 31 ± 6*
Tetrols 0.05 ± 0.09 27 ± 6# 5 ± 4# 23 ± 5*
Pentols 0.03 ± 0.03 6 ± 1# 3 ± 2# 7 ± 1*
Total PHBAs 4 ± 3 508 ± 173# 244 ± 110# 657 ± 64*
Total BAs 519 ± 390 987 ± 188 1779 ± 162# 1397 ± 198
TCA/tot. BAs [%] 59 ± 26 3 ± 3# 4 ± 2# 2 ± 1
PHBA/tot. BAs [%] 0.8 ± 0.6 51 ± 24# 14 ± 6# 47 ± 5*
 Total BAs includes also PHBAs.
#Significant difference from WT Ctrl; ⁄significant difference from WT CBDL;
p <0.05.
BA, Bile acid; CA. LCA. DCA. CDCA. HDCA. UDCA. MCA: cholic. lithocholic.
deoxycholic. chenodeoxycholic. hyodeoxycholic. ursodeoxycholic. muricholic
acids; PHBA, polyhydroxylated (tetra- and pentahydroxylated) BAs; T indicates
taurine conjugation.
Statistical analysis was performed using one-way analysis of variance test fol-
lowed by Student’s t test.
Table 2. Liver bile acids in WT and BSEP/ mice before and after DDC feeding.
WT Ctrl
[pmol/mg]
BSEP-/- Ctrl
[pmol/mg]
WT DDC
[pmol/mg]
BSEP-/- DDC
[pmol/mg]
TCA 205 ± 121 79 ± 67 412 ± 387 61 ± 19*
TUDCA 2 ± 1 3 ± 1 11 ± 13# 2 ± 1
TCDCA 4 ± 2 4 ± 2 20 ± 17 5 ± 1*
TDCA 7 ± 4 2 ± 4 0.36 ± 0.22# n.d.
TLCA 0.15 ± 0.05 0.04 ± 0.04# 0.14 ± 0.08 0.07 ± 0.03
CA 5 ± 9 0.6 ± 0.4# 5 ± 7 0.18 ± 0.18*
TοMCA 55 ± 31 48 ± 40 462 ± 580 20 ± 4*
TαMCA 17 ± 8 11 ± 3 49 ± 67 7 ± 2
TβMCA 133 ± 83 642 ± 405# 2431 ± 675# 650 ± 164*
οMCA 1 ± 1 0.34 ± 0.16 2 ± 2 n.d.
βMCA 1 ± 2 11 ± 6# 6 ± 4 7 ± 4
T-Tetrols 3 ± 2 2426 ± 1941# 396 ± 153# 2968 ± 1486*
T-Pentols n.d. 515 ± 271# 69 ± 26# 113 ± 60
Total PHBAs 3 ± 2 2472 ± 1971# 412 ± 160# 3080 ± 1523*
Total BAs 380 ± 286 3273 ± 2008# 3509 ± 776# 4036 ± 1651
TCA/tot. BAs [%] 47 ± 35 2 ± 2# 12 ± 11 1 ± 0.4*
PHBAs/tot. BAs [%] 0.8 ± 0.4 75 ± 60# 12 ± 4# 76 ± 37*
Total BAs includes also PHBAs.
#Significant difference from WT Ctrl; ⁄significant difference from WT DDC;
p <0.05.
BA, Bile acid; CA. LCA. DCA. CDCA. HDCA. UDCA. MCA: cholic. lithocholic.
deoxycholic. chenodeoxycholic. hyodeoxycholic. ursodeoxycholic. muricholic
acids; PHBA, polyhydroxylated (tetra- and pentahydroxylated) BAs; T indicates
taurine conjugation.
Statistical analysis was performed using one-way analysis of variance test fol-
lowed by Student’s t test.
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Fig. 5. BSEP/ mice are metabolically preconditioned with a hydrophilic bile
acid pool. (A and B) Real-time PCR was used to assess the mRNA expression of
Cyp2b10 and Cyp3a11. While Cyp2b10 remained normal at baseline in BSEP/
mice mRNA levels of Cyp3a11 are elevated. After (A) CBDL Cyp2b10 was increased
in BSEP/ mice while Cyp3a11 remained unchanged. (B) DDC feeding did not
affect Cyp2b10 and Cyp3a11 expression in BSEP/ mice. Expression values were
normalized against 36b4 levels and are shown relative to expression level in
unchallenged WT animals. #Significant difference from WT control; ⁄significant
difference from WT CBDL; p <0.05. Statistical analysis was performed using one-
way analysis of variance test followed by Student’s t test.
JOURNAL OF HEPATOLOGYmice towards a more hydrophilic and thus less toxic BA profile,
both at baseline and with bile duct injury ceased by CBDL or
DDC. Interestingly, hepatic levels of the potentially toxic BA
TCA were at baseline more than 7-fold higher in WT than in
BSEP/ mice (Tables 1 and 2). In contrast, tetra- and pentahy-
droxylated BAs (PHBAs) were almost absent at baseline in WT
control mice but increased more than 100-fold in BSEP/ mice
(Tables 1 and 2). Levels of PHBAs increased inWTmice after CBDL
whereas they did not change in BSEP/ CBDL mice. However, the
ratio between potentially toxic TCA and non-toxic PHBAs (TCA/
PHBA) showed that toxic TCA still was predominant in the BA
pool of WT CBDL mice whereas in BSEP/ mice CBDL mice,
PHBAs were the most prevalent BAs (Tables 1 and 2).
mRNA expression levels of Cyp2b10 and Cyp3a11 (the down-
stream targets of the two main nuclear receptors regulating hep-
atic BA hydroxylation constitutive androstane receptor (CAR) and
pregnane X receptor (PXR)), were increased in BSEP/ mice at
baseline (Fig. 5A, B). Consistent with the suggested increase in
CAR activity, MRP4, which is a CAR-regulated basolateral alterna-
tive BA transporter [17], was expressed at higher levels in
BSEP/ mice before and after CBDL (Supplementary Fig. 3B, left
panel). The same observation was made for MRP3, while baseline
protein levels of MRP2 and organic anion-transporting polypep-
tide (OATP) as well as Na+-taurocholate co-transporting polypep-
tide (NTCP) were reduced in BSEP/ mice compared to WT mice
(Supplementary Fig. 3B, left panel). The changes in protein
expression levels of BA transporters in DDC fed animals were
remarkably similar to those in bile duct ligated mice. As such,Journal of Hepatology 20MRP4 and MRP3 were increased in BSEP/ control mice while
for MRP2, OATP and NTCP a reduction was found (Supplementary
Fig. 3B, right panel).
BSEP/ mice are protected against increases in biliary pressure after
bile duct ligation
Since appearance of bile infarcts as seen in WT CBDL mice
(Fig. 1A) is determined by increased biliary pressure [8], we
explored potential changes in biliary pressure in our mouse17 vol. 66 j 95–101 99
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model. In WT mice (grey line) a steady increase in biliary pres-
sure from 15 mmH2O to 47 mmH2O could be observed over a
period of 135 s after CBDL. In contrast, biliary pressure in BSEP/
mice (black line) showed only marginal increases (from 5 to 11
mmH2O) over the same time period. Already after 60 s of mea-
surement significant differences in biliary pressure of WT mice
(grey line) and BSEP/ mice (black line) were evident (Supple-
mentary Fig. 4).Discussion
Our study demonstrates that mice lacking BSEP are metabolically
preconditioned and thereby protected against acquired/exter-
nally afflicted cholestatic liver and bile duct injury. This protec-
tion against cholestatic liver and bile duct injury induced by
CBDL or DDC feeding in BSEP/ mice may at least in part be
explained by increased BA hydroxylation pathways resulting in
a more hydrophilic (and therefore less toxic) BA pool in these
mouse models. Accordingly, we could show that BA hydroxylat-
ing cytochromes Cyp2b10 and Cyp3a11, which are downstream
targets of nuclear receptors CAR and PXR, were increased in
BSEP/ mice already at baseline suggesting that this mouse
model is preconditioned with a more hydrophilic (less toxic) BA
pool. In line, alternative efflux pumps MRP3 and 4 were induced.
Although the function of BSEP is missing in this mouse model, no
significant difference in bile flow between WT and BSEP/ mice
has been found previously [5]. Therefore, it has been suggested
that other transporters – namely Mdr1a and Mdr1b – may com-
pensate for hepatobiliary BA transport in BSEP/ mice [18,19].
However, in our mice gene expression levels of these two trans-
porters remained unchanged (data not shown). Interestingly in
our mice, bile flow was severely diminished and impossible to
measure, which is in line with the low biliary pressure we found
in these mice even after 7 days of bile duct ligation (Supplemen-
tary Fig. 4).
Our observation that increased levels of polyhydroxylated BAs
(PHBAs) are accompanied by protection from cholestatic liver
injury are in line with the finding that WTmice subjected to CBDL
after treatment with agonists for CAR and PXR developed less
liver injury than non-treated WT CBDL mice [20]. However, life-
long preconditioning with a hydrophilic BA pool (as seen in
BSEP/ mice) may have a more pronounced protective effect
than agonist treatment. Of note, BSEP/ mice were not protected
from cholic acid induced cholestasis [21], which may be
explained by the fact that cholic acid feeding resulted in a poten-
tially more hydrophobic BA pool. 51% of total BAs in livers of
BSEP/ mice were PHBAs, with taurine-conjugated tetrahydrox-
ylated BAs as the most prominent fraction whereas in WT mice
less than 1% of PHBAs were present at base line. Conversely,
TCA, which in mice is thought to be pro-inflammatory [22] was
the most prominent BA in WT mice at baseline. The finding that
lipopolysaccharide (released from the gut) does not stimulate
cytokine production during early stages of cholestasis [22],
underlines the assumption that other stimuli (such as BAs) trig-
ger inflammation under cholestatic conditions. Moreover, it has
been shown that loss of macrophages does not attenuate liver
injury in bile duct ligated mice [23,24], implying that cell types
other than macrophages (such as hepatocytes and cholangio-
cytes) elicit production of inflammatory mediators [22]. Exposure
of hepatocytes to TCA increased expression levels of several100 Journal of Hepatology 20inflammatory mediators such as cytokines, chemokines, adhesion
molecules and enzymes involved in arachidonic acid metabolism
in vitro [22]. In line with these literature findings, expression of
genes such as Mcp1 (Fig. 2B), Icam, Cox2 and Cxcl2 (Supplemen-
tary Fig. 5) was increased inWTmice after CBDL (and not affected
in BSEP/ CBDL mice), suggesting that the potentially toxic BA
pool in WT CBDL mice contributes to the chemokine milieu
which is responsible for lymphocyte and neutrophil recruitment
in the liver, subsequently inducing inflammation.
The finding that the BA profile of BSEP/ mice protects from
the development of BA induced cholestatic liver and bile duct
injury with inflammation and biliary fibrosis may be attributed
to at least two different mechanisms. First the high concentration
of hydrophilic BAs in the BA pool of BSEP/ mice may simply
have a diluting effect and therefore could attenuate the toxic bile
effect. Second PHBAs may have an anti-inflammatory effect via
interaction (suppressor effect) of key regulators of inflammatory
pathways (e.g., early growth response protein [1Egr-1] [22]),
which needs to be addressed by follow-up studies. In addition
to changes in bile composition attenuating the toxicity of bile,
low biliary pressure, which was found in BSEP/mice after CBDL,
may also contribute to the protection of BSEP/ mice against
cholestatic injury. Increased biliary pressure after CBDL in WT
mice causes bile infarcts seen on the histology of these mice.
Thus, in addition to the preconditioning of BSEP/ mice with a
hydrophilic BA pool also the low pressure in their biliary system
after CBDL may protect this mouse model from cholestatic liver
injury. Finally, less toxic bile composition per sewith more hydro-
philic BAs may also have protective action [25]. Since not only
CBDL but also DDC fed mice as models of cholangiopathy with
features of sclerosing cholangitis [9] were protected against cho-
lestatic injury, PHBAs move into the perspective of potential
treatment strategies of cholestatic liver disease such as primary
sclerosing cholangitis and primary biliary cirrhosis.
In conclusion, our study demonstrates that increased BA
hydroxylation and subsequent reduced bile toxicity together
with a low biliary pressure result in protection from cholestatic
liver injury. Our observations made in BSEP/ mice may have
implication for the human situation by considering PHBAs – or
activators of enzymes involved in BA hydroxylation – as potential
therapeutic strategies for pharmacological treatment of chole-
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